Following ongoing deals with Bristol Myers Squibb Co. and Eli Lilly and Co., AI and machine learning firm Insitro Inc. has ...

An observational study of 70,257 U.S. patients with both schizophrenia and type 2 diabetes has added weight to the emerging ...

In line with expectations, Iambic Therapeutics Inc. went public Oct. 15, pricing its IPO of 9.375 million shares at $16 apiece for gross proceeds of about $150 million. Another $22.5 million could ...

Just in time for the flu season, Sanofi SA has reached an agreement to resolve the EU Commission’s preliminary concerns about ...

Altay Therapeutics Inc. has completed a $37 million series A financing as it advances development of novel small-molecule transcription factor inhibitors.

Takeda Pharmaceutical Co. Ltd. has quantified the potential convenience advantage of its 20% facilitated subcutaneous ...

Omass Therapeutics Ltd. has raised £230 million (US$305 million) in a series C after transitioning to a clinical-stage company, and is now funded to take the lead program through phase II and move a ...

Scientists at Moderna Inc. are seeking a solution to the rapid emergence of viral variants that escape treatments. Many monoclonal antibodies (mAbs) initially work well against a single target but ...

New antisense oligonucleotide (ASO) approaches are expanding the therapeutic options for cystic fibrosis (CF), targeting both the underlying genetic defects and the downstream consequences of impaired ...

Galibra Neuroscience Inc. has established a manufacturing partnership with Genezen Laboratories Inc. to advance Galibra’s GAL-005 program, an AAV-based gene therapy for succinic semialdehyde ...

Shaanxi Micot Pharmaceutical Technology Co. Ltd. recently presented data on MT-200605, a tropomyosin receptor kinase B (TrkB) ...

Carnyx Therapeutics Ltd. has unveiled CNYX-005, its lead oral sleep candidate. CNYX-005 emerged from research into peptide ...